Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-Alpha vs. Imatinib/Low-Dose AraC vs. Interferon-Alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase

Trial Profile

Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-Alpha vs. Imatinib/Low-Dose AraC vs. Interferon-Alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Imatinib (Primary) ; Cytarabine; Hydroxycarbamide; Interferon alpha
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms CML Study IV
  • Most Recent Events

    • 06 Jun 2017 Ten-year overall survival results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2012 Status changed from recruiting to active, no longer recruiting according to abstract presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top